The Chen-Huang Center for EGFR-Mutant Lung Cancers aims to advance care and research of EGFR-mutant lung cancer with clinical trials of new and novel therapies supported by lab research and studies of cancer genetics.
Our trials include studies for patients with newly diagnosed EGFR-mutant lung cancer and patients whose cancer has advanced on current therapy, in addition to studies of cancer genetics.
A patient must meet certain requirements to participate in a clinical trial. Your doctor or another member of your health care team is the best resource for knowing your treatment options and eligibility.
EGFR Inhibitor Naïve
For patients that are newly diagnosed or have not yet started treatment for EGFR-mutant lung cancer:
- 22-331 – A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib
- 20-601 – Phase I Trial of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib
- 18-070 – Phase II study of osimertinib with on-study and post-progression biopsies
EGFR Inhibitor Resistant
For patients that have had their EGFR-mutant lung cancer treated with targeted therapy already and have developed disease progression or relapse:
- 23-546 – A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)
- 23-327 – A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects with Advanced/Metastatic Solid Tumors
- 22-491 – A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients with Active Epidermal Growth Factor Receptor Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer
- 21-249 – Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1 Inhibitor
- 20-601 – Phase I Trial of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib
EGFR Exon 20 Previously Treated
For patients that have had their lung cancer with EGFR exon 20 insertion mutation treated and have developed disease progression or relapse:
- 22-698 – An Open-Label, Phase 1/1b Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- 21-249 – A Phase 2 Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on or are Intolerant to a PD-1/L1, EGFR, or ALK Inhibitor
Translational Research Studies
The Chen-Huang Center for EGFR-Mutant Lung Cancers brings together clinical researchers and scientists dedicated to improving our understanding of the EGFR gene. As our researchers continue to gather data and results from studies like the ones below, they hope to uncover new details about the gene mutation that will lead to new standardized treatment options:
Collection of Specimens and Clinical Data from Subjects with Proven or Suspected Thoracic Malignancies
One of the key goals of the Chen-Huang EGFR Center is to build a "biobank" of patients with known EGFR gene mutations. To build this biobank, our thoracic disease center has a dedicated team of research data specialists who coordinate and facilitate consent enrollment of patients who have been seen in our clinics. Patients consent to allow the EGFR Center and our thoracic physicians to follow their course of care through their medical records, in addition to making use of leftover tissue samples and blood banking for research purposes. Through analyses of the data obtained from our patients' medical records and linking this information to their samples, the EGFR Center can conduct this research. The EGFR Center continues to assess our patients' treatment outcomes, determine which treatment works best against the EGFR driver, and confirm the ways acquired resistance may occur in patients who had EGFR-related targeted treatment. We hope this continued research will translate to the creation of newly approved standard of care treatments for this patient population.
Biology of Young Lung Cancer Study
Pasi Janne, MD, PhD, has an ongoing Biology of Young Lung Cancer study within Dana-Farber's Lowe Center for Thoracic Oncology. This study was created with the goal of better understanding why a significant percentage of lung cancer patients developed their diagnosis at the age of 45 years and younger. From the current literature, younger patients with lung cancer have been linked to a higher likelihood of harboring a gene mutation that drives their cancer. It has been noted that approximately 40% of young lung cancer patients harbor the EGFR gene. Within this context, the study aims to provide clinical germline testing of participants through a blood test, in addition to blood banking that can be used for future research purposes. We offer this study for internal Dana-Farber patients, as well as remote patients who reside in the United States.